<DOC>
	<DOCNO>NCT00561691</DOCNO>
	<brief_summary>Determination efficiency nimotuzumab child diffuse intrinsic pontine glioma .</brief_summary>
	<brief_title>Nimotuzumab Children With Intrinsic Pontine Glioma</brief_title>
	<detailed_description>Due poor prognosis diffuse intrinsic pontine glioma , limited therapy option , relevant portion EGFR expression unexpected good response therapy OSAG 101 phase II study , phase III study plan newly diagnose diffuse intrinsic pontine glioma child adolescent . A phase II study patient recurrence/resistance high grade glioma childhood adolescence show , particular , part intrinsic pontine glioma response monotherapy OSAG 101 result reduction size tumour stabilisation growth tumour . Together clinical improvement , stabilisation last markedly 6 month two third patient . The current phase III study schedule provide evidence effectiveness case newly diagnose intrinsic pontine glioma . In study , OSAG 101 give concomitantly standard therapy kind tumour , i.e . fractionate radiotherapy , show effectiveness primary endpoint median progression-free survival , secondary endpoint median overall survival side effect profile . Evidence median progression-free survival side effect profile combination meet expected result one may consider combination therapy therapeutic approach immunotherapeutic antiangiogenic approach and/or mild chemotherapy could lead good prognosis quality life patient .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<criteria>Histology stag disease : Newly diagnose intrinsic pontine glioma document MRI measurable least one dimension Histology require study , tumour biopsy recommend General condition Age ≥ 3 year ≤ 20 year , gender Life expectancy ≥ 4 week Performance status ECOG ≥ 3 Karnofsky/Lansky status ≥ 40 % Adequate haematological , renal , hepatic function Absolute leukocyte count ≥ 2.0 x 109/l Haemoglobin ≥ 10 g/dl Platelets ≥ 50 x 109/l Bilirubin total ≤ 2.5 x ULN ALT/AST ≤ 5.0 x ULN Creatinine i. S. ≤ 1.5 x ULN Prior/initial examination ( within 14 day prior start therapy ) : Cranial MRI ( estimation index lesion ) Clinical internal neurological examination ; body weight , height , surface , Performance status ECOG , Karnofsky Lansky Blood cell count , blood gas analysis ; serum analysis electrolyte ( Na , K , Ca , Mg ) , chloride , phosphate , creatinine , BUN , AST , ALT , bilirubin , GGT , LDH , lipase , total protein , CRP , blood sugar ; coagulation test ( Quick , PTT , TT ) ; urinalysis EKG , echocardiography case positive cardiac history Pregnancy test female childbearing age Other criterion Planned day first antibody application within 14 day MRI Written sign informed consent patient and/or parent legal guardian ( ) ( ) inform Negative pregnancy test female childbearing age Treatment study centre Availability patient study treatment ability comply study plan Pontine glioma secondary malignancy Low grade brain stem glioma ( i.e . focal , cervicomedullar , tectal brain stem glioma ) Other severe underlie disease preexist serious condition bear risk inadequate study treatment ( e.g . severe mental retardation , severe statomotoric retardation , severe cerebral palsy , congenital syndrome ) Prior antineoplastic therapy , inclusively chemotherapy , immunotherapy , radiotherapy Prior administration recombinant human mural antibody know hypersensitivity antibody Simultaneous antineoplastic therapy study treatment Participation another therapeutic study experimental treatment involve underlying cancer disease Pregnancy , lactate mother inadequate contraception female male childbearing age</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>diffuse instrinsic ponitine glioma , brainstem</keyword>
</DOC>